Compare TENX & LE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TENX | LE |
|---|---|---|
| Founded | 1967 | 1963 |
| Country | United States | United States |
| Employees | N/A | 3900 |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.8M | 365.5M |
| IPO Year | 2001 | 1994 |
| Metric | TENX | LE |
|---|---|---|
| Price | $13.50 | $11.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $29.67 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 1.2M | 239.1K |
| Earning Date | 05-15-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 10.56 |
| Revenue | N/A | ★ $1,162,769,000.00 |
| Revenue This Year | N/A | $5.53 |
| Revenue Next Year | N/A | $2.48 |
| P/E Ratio | ★ N/A | $1.13 |
| Revenue Growth | N/A | ★ 0.72 |
| 52 Week Low | $5.67 | $10.01 |
| 52 Week High | $18.38 | $20.04 |
| Indicator | TENX | LE |
|---|---|---|
| Relative Strength Index (RSI) | 64.01 | 47.71 |
| Support Level | $13.16 | $10.35 |
| Resistance Level | $14.15 | $11.82 |
| Average True Range (ATR) | 0.81 | 0.76 |
| MACD | 0.31 | -0.04 |
| Stochastic Oscillator | 91.71 | 41.98 |
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Lands' End Inc is a United States-based digital retailer of solution-based apparel, swimwear, outerwear, accessories, footwear, home products, and uniforms. It offers products online at the website (www.landsend.com), through third-party distribution channels, its own company-operated stores, and third-party license agreements. Lands' End also offers products to businesses and schools, for their employees and students, through the Outfitters distribution channel. The company's operating segments consist of: U.S. eCommerce, Europe eCommerce, Outfitters, Third Party, Licensing, and Retail. The majority of its revenue is generated from the U.S. eCommerce segment. Geographically, Lands' End derives maximum revenue from the United States, and the rest from Europe and other markets.